Aurinia Pharmaceuticals Inc. (AUPH) News Headlines

▮ More

Date

Headline

5/10/2022 6:15:34 AM Aurinia Pharma Q1 Net Loss $37.6 Mln Or $0.27/shr Vs. Net Loss $50.4 Mln Or $0.40/shr Last Year

2/28/2022 10:14:08 AM Aurinia Pharmaceuticals Stock Tanks 30% After Reporting Q4 Results

2/28/2022 6:06:41 AM Aurinia Q4 Net Loss $33.3 Mln Or $0.25/Shr Vs Loss Of $8.1 Mln Or $0.06/Shr Last Year

12/29/2021 10:48:49 AM Aurinia Pharmaceuticals Down 3%

12/9/2021 7:24:20 AM Pre-market Movers: ENSC, RETA, CCNC, PEAR, SYTA…

12/9/2021 6:27:05 AM Aurinia Announces Positive Topline Results From AURORA 2 Continuation Study Of LUPKYNIS For Active Lupus Nephritis

11/22/2021 10:33:36 AM Aurinia Pharma Falls More Than 25%; Downtick Continues

11/22/2021 7:37:35 AM Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR…

11/1/2021 10:26:05 AM Aurinia:reductions In Proteinuria Sustained With No Impact On Renal Function At 30 Months Of Treatment With Voclosporin

8/17/2021 10:35:24 AM Aurinia Pharmaceuticals Declines 9% Following Acquisition Of Two Pipeline Assets

8/17/2021 6:09:10 AM Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune And Kidney-related Diseases

6/7/2021 7:24:47 AM Aurinia Announces Additional Analysis Of AURORA 1 Phase 3 Study Data Presented At ERA-EDTA 2021 Congress

4/8/2021 6:08:36 AM Aurinia Pharma Presents Addl Efficacy Data From AURA-LV And AURORA 1 Pivotal Trials Of LUPKYNIS In Lupus Nephritis

3/15/2021 6:15:45 AM Aurinia Announces Positive Cost-Effectiveness Assessment Of LUPKYNIS In Latest ICER Draft Evidence Report

2/22/2021 1:32:00 AM New Drugs Approved In January

1/23/2021 2:51:35 AM FDA Approves Aurinia Pharma's Lupkynis - Second Lupus Nephritis Drug In A Month

1/22/2021 5:37:33 AM Pre-market Movers In Healthcare Sector: ADMP, FLDM, ATOS, AUPH, SENS...

1/11/2021 3:04:31 AM Will Aurinia Pharma's Lupus Nephritis Drug Pass FDA Muster?

2/8/2018 6:14:48 AM RBC Capital Markets Starts Aurinia Pharmaceuticals Inc. (AUPH) At Outperform With $9 Price Target

Older Articles